Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225.
Dosimetry
PSMA-617
PSMA-TO-1
Prostate cancer
Radioligand therapy
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
01 Oct 2022
01 Oct 2022
Historique:
received:
06
06
2022
accepted:
16
09
2022
entrez:
1
10
2022
pubmed:
2
10
2022
medline:
2
10
2022
Statut:
epublish
Résumé
PSMA-TO-1 ("Tumor-Optimized-1") is a novel PSMA ligand with longer circulation time than PSMA-617. We compared the biodistribution in subcutaneous tumor-bearing mice of PSMA-TO-1, PSMA-617 and PSMA-11 when labeled with First, PET images of Tumor uptake measured by PET imaging of PSMA-TO-1 tumor uptake tended to be greater than that of PSMA-617 in both preclinical and clinical settings. Mice treated with
Sections du résumé
BACKGROUND
BACKGROUND
PSMA-TO-1 ("Tumor-Optimized-1") is a novel PSMA ligand with longer circulation time than PSMA-617. We compared the biodistribution in subcutaneous tumor-bearing mice of PSMA-TO-1, PSMA-617 and PSMA-11 when labeled with
METHODS
METHODS
First, PET images of
RESULTS
RESULTS
Tumor uptake measured by PET imaging of
CONCLUSIONS
CONCLUSIONS
PSMA-TO-1 tumor uptake tended to be greater than that of PSMA-617 in both preclinical and clinical settings. Mice treated with
Identifiants
pubmed: 36182983
doi: 10.1186/s13550-022-00935-6
pii: 10.1186/s13550-022-00935-6
pmc: PMC9526774
doi:
Types de publication
Journal Article
Langues
eng
Pagination
65Subventions
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016042
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
J Nucl Med. 2021 Jul 1;62(7):884-885
pubmed: 33384321
Pharmaceuticals (Basel). 2017 Jun 21;10(2):
pubmed: 28635637
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51
pubmed: 26318602
J Nucl Med. 2020 Nov;61(11):1544-1552
pubmed: 33037092
Dose Response. 2018 Jan 22;16(1):1559325817747387
pubmed: 29383010
J Nucl Med. 2021 Jul 1;62(7):989-995
pubmed: 33277393
Eur Urol. 2019 Jun;75(6):920-926
pubmed: 30473431
J Nucl Med. 2017 Jul;58(7):1017-1018
pubmed: 28408527
Radiat Res. 2005 Jul;164(1):100-9
pubmed: 15966769
J Nucl Med. 2018 Nov;59(11):1699-1705
pubmed: 29653971
J Nucl Med. 2020 Jun;61(6):857-865
pubmed: 31732676
J Nucl Med. 1999 Feb;40(2):37S-61S
pubmed: 10025848
Curr Radiopharm. 2018;11(3):200-208
pubmed: 29732998
Lab Anim Sci. 1999 Jun;49(3):319-23
pubmed: 10403450
J Nucl Med. 2021 Feb;62(2):228-231
pubmed: 32646877
J Nucl Med. 2019 Apr;60(4):517-523
pubmed: 30291192
Bioconjug Chem. 2012 Apr 18;23(4):688-97
pubmed: 22369515
Clin Cancer Res. 2020 Jun 15;26(12):2946-2955
pubmed: 31932492
J Nucl Med. 2017 Nov;58(11):1786-1792
pubmed: 28546332
Z Med Phys. 2015 Sep;25(3):264-74
pubmed: 25791740
PLoS One. 2015 Aug 19;10(8):e0136204
pubmed: 26287527
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):148-158
pubmed: 30090965
Theranostics. 2020 Feb 3;10(6):2612-2620
pubmed: 32194823
J Nucl Med. 2016 Jan;57(1):151-62
pubmed: 26471692
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
J Nucl Med. 2005 Jun;46(6):1023-7
pubmed: 15937315
Adv Drug Deliv Rev. 2008 Sep;60(12):1371-82
pubmed: 18514364
Semin Nephrol. 2003 Sep;23(5):486-99
pubmed: 13680538
J Nucl Med. 2021 Mar;62(3):386-392
pubmed: 32826319